Market Research Logo

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2018

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hypogonadism - Pipeline Review, H2 2018, provides an ove


Introduction
Global Markets Direct Report Coverage
Secondary (Hypogonadotropic) Hypogonadism - Overview
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
Diurnal Group Plc
Merck & Co Inc
Mereo Biopharma Group Plc
Repros Therapeutics Inc
Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
Featured News & Press Releases
Jan 26, 2018: Repros Announces Negative Opinion From the EMA for Enclomiphene
Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism
Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities
Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism
Aug 15, 2016: Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Jun 01, 2016: Repros Provides Update on EU Submission of Enclomiphene for the Treatment of Secondary Hypogonadism and 3 Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men
Mar 15, 2016: Repros Announces Initiation of Formal Approval Process by the European Medicines Agency
Feb 16, 2016: Repros Completes Randomization of Enclomiphene Phase 2 Proof of Concept Study in Obese Secondary Hypogonadal Men
Feb 08, 2016: Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism
Jan 11, 2016: Repros Announces Court of Appeals' Affirmation of Summary Judgment in Favor of the Company
Jan 04, 2016: Repros Updates Enclomiphene Program
Dec 01, 2015: Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, H2 2018
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, H2 2018
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2018
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2018
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H2 2018
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report